

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

**U.S. Serial No.: 10/789,627**

**Applicants: Kaufman et al.**

**Filed: February 26, 2004**

**Confirmation No.: 7662**

**Group Art Unit: 1632**

**Examiner: Anoop Kumar Singh**

**Title: Composition for Delivering an Agent to a Target Cell and Uses thereof**

Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

**AMENDMENT IN RESPONSE TO JULY 9, 2008 NON-FINAL OFFICE ACTION**

This paper is being filed in reply to the July 9, 2008 Office Action issued by the U.S. Patent and Trademark Office. A response is due on October 9, 2008, therefore, this paper is being timely filed.

**Amendments to the Claims** begins on page 3 of this paper.

**Remarks** begin on page 9 of this paper.

This submission also includes:

- 1) **Exhibit A** [submitted herewith an IDS]: Bereta et al., "Improving tumor targeting and therapeutic potential of Salmonella VNP20009 by displaying cell surface CEA-specific antibodies," (2007) *Vaccine* 25(21):4183-92;
- 2) **Exhibit B** [submitted herewith an IDS]: Van Crielinge and Beyaert, "Yeast Two-Hybrid: State of the Art," (1999) *Biol Proced Online* 2(1): 1-38;
- 3) **Exhibit C** [submitted herewith an IDS]: Phizicky and Fields, "Protein-Protein Interactions: Methods for Detection and Analysis," (1995) *Microbiological Reviews*, 59(1): 94-123;
- 4) **Exhibit D** [submitted herewith an IDS]: Theriot, "The Cell Biology of Infection by Intracellular Bacterial Pathogens," (1995) *Ann Rev. Cell Dev Biol*, 11: 213-39;

- 5) Exhibit E [previously submitted in an IDS]: Toso et al., “Phase I study of the intravenous administration of attenuated *Salmonella typhimurium* to patients with metastatic melanoma” (2002) *J Clin Oncol.* 20(1):142-52; and
- 6) Exhibit F [previously submitted in an IDS]: Medina and Guzman, “Use of live bacterial vaccine vectors for antigen delivery: potential and limitations,” (2001) *Vaccine* 19(13-14):1573-80.